Ignore cranky pants KPI. All this talk of a possible CR gets his knickers in a twist.
The three digit numeric code is the sequence number of the trial. "009" refers to the BIT225-009 trial, ie the 9th human trial for Biotron's lead compound which is entitled BIT225. That was a HIV trial.
It can be confusing because the same compound was also used to target the Hep C virus in previous trials such as my reference to "008", ie the BIT225-008 trial.
Here is a list of the older BIT225 trials and their sequence numbers. Since then we have seen results for BIT225-009 and are currently awaiting results for BIT225-010, BIT225-011 and BIT225-012 any week now.
BIT225 Clinical Program
• BIT225-‐001: Phase 1a, single dose, dose escalaBng study in healthy volunteers (48 subjects; Aust)
• BIT225-‐003: Phase 1b, 7-‐day, repeat dose study in HCV+ paBents (35 and 200 mg BID; 18 subjects; Aust)
• BIT225-‐004: Phase 2a, 10-‐day, repeat dose study in HIV+ paBents (400 mg BID; 21 subjects; Thailand)
• BIT225-‐005: Phase 2a, 28-‐day, repeat dose study in HCV G1 paBents in combinaBon with PEG/RBV (200 and400 mg BID; 24 paBents; Thailand)
• BIT225-‐006: Phase 2, 28-‐day, repeat dose, open label study in HIV/HCV G1 and 3 co-‐infected paBents incombinaBon with PEG/RBV (300 mg BID; 12 paBents; Thailand)
• BIT225-‐007: Phase 1, BE/PK study in healthy volunteers, cross-‐over, single dose comparing capsuleformulaBon with exisBng powder (400 mg BID; 12 subjects; Aust)
• BIT225-‐008: Phase 2, 3 month, repeat dose study in HCV+ paBents (G1 & 3) in combinaBon with PEG/RBV(200 mg BID (capsule formulaBon); 60 subjects; Thailand)
Expand
